Jai N Patel
Overview
Explore the profile of Jai N Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel J, Chaihorsky L, Dong O, Lu C, Moretz C, Reese E, et al.
Am J Manag Care
. 2025 Feb;
31(2):e47-e55.
PMID: 39977287
Objectives: To evaluate medical policy determinations for pharmacogenetic (PGx) testing for 65 clinically relevant drug-gene pairs and evidence cited to support determinations across major US health plans and laboratory benefit...
2.
Ho T, Smith D, Aquilante C, Cicali E, El Rouby N, Hertz D, et al.
Clin Pharmacol Ther
. 2025 Jan;
PMID: 39887719
The safety of systemic fluoropyrimidines (e.g., 5-fluorouracil, capecitabine) is impacted by germline genetic variants in DPYD, which encodes the dihydropyrimidine dehydrogenase (DPD) enzyme that functions as the rate-limiting step in...
3.
Nugent K, Huang L, Patel J, Hertz D
Pharmacogenet Genomics
. 2025 Jan;
35(3):101-109.
PMID: 39832190
Ibrutinib treatment is often complicated by cardiovascular side effects (CVSEs). The objective of this retrospective pharmacogenetic study is to replicate a previously reported association of 'high-risk' patients, who are homozygous...
4.
Steuerwald N, Morris S, Nguyen D, Patel J
JCO Oncol Pract
. 2024 Nov;
20(11):1441-1451.
PMID: 39531848
Pharmacogenomic (PGx) testing is a growing area of personalized medicine with demonstrated clinical utility in improving patient outcomes in oncology. PGx testing of pharmacogenes affecting drug pharmacokinetics, pharmacodynamics, and response...
5.
Benfield M, He J, Arnall J, Kaizen W, Jandrisevits E, Eboli-Lopes K, et al.
Transplant Cell Ther
. 2024 Nov;
31(2):111.e1-111.e10.
PMID: 39505211
Malignancy is a well-known risk factor for venous thromboembolism (VTE), and the Khorana risk score is effective for screening patients with solid tumors. However, there is a lack of validated...
6.
Cavallari L, Hicks J, Patel J, Elchynski A, Smith D, Bargal S, et al.
Pharmacogenet Genomics
. 2024 Nov;
35(1):1-11.
PMID: 39485373
Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual's genotype in conjunction with other important clinical factors. Despite significant evidence of genetic...
7.
Patel J, Morris S, Nguyen D
J Natl Compr Canc Netw
. 2024 Oct;
22(8).
PMID: 39413814
No abstract available.
8.
Tracksdorf T, Smith D, Pearse S, Cicali E, Aquilante C, Scott S, et al.
Support Care Cancer
. 2024 Jul;
32(8):497.
PMID: 38980476
Purpose: Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for severe and fatal toxicity from fluoropyrimidine (FP) chemotherapy. Pre-treatment DPYD testing is standard of care in many countries,...
9.
Nguyen D, Morris S, Hamilton A, Kwange S, Steuerwald N, Symanowski J, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2300623.
PMID: 38935897
Purpose: Fluoropyrimidine-related toxicity and mortality risk increases significantly in patients carrying certain genetic variants with standard dosing. We implemented genotyping at a multisite cancer center and evaluated its impact on...
10.
Patel J, Singh J, Ghosh N
Oncotarget
. 2024 Jun;
15:355-359.
PMID: 38829647
Ibrutinib was the first Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL). While producing durable responses and prolonging survival, roughly 20-25% of...